Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $10.53 Analyst target: $42.50 Upside: 303.61%
MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of allogeneic, ready-to-use, invariant natural killer T-cell therapies for treating cancer and other immune-mediated diseases. The company is headquartered in New York, New York.
See the full interactive analysis & chart →Informational only — not investment advice.